MABE416
Anti-Cisplatin DNA Adducts Antibody, clone ICR4
clone 1CR4, from rat
Synonim(y):
CP9/19, Cisplatin DNA modification
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
About This Item
Kod UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Polecane produkty
pochodzenie biologiczne
rat
Poziom jakości
forma przeciwciała
purified antibody
rodzaj przeciwciała
primary antibodies
klon
1CR4, monoclonal
reaktywność gatunkowa
human
metody
ELISA: suitable
dot blot: suitable
immunohistochemistry: suitable
izotyp
IgG2aκ
Warunki transportu
wet ice
docelowa modyfikacja potranslacyjna
unmodified
Opis ogólny
Cisplatin adducts are Guanine-Guanine (GG) DNA intrastrand cross links caused by the chemical compound Cisplatin. Cisplatin is used as a chemotherapy agent that contains platinum. The crosslinking of the DNA triggers apoptosis in the effected cell. Cisplatin is particularly effective in certain cancers such as testicular cancer. Unfortunately like most chemotherapy agents Cisplatin has many side effects and cancer cells typically will develop resistance to the drug after a period of time. Clone ICR4 was formerly known as clone CP9/19.
Specyficzność
This antibody demonstrates specificity for cisplatin modified DNA.
Immunogen
Cisplatin modified native DNA.
Zastosowanie
Detect Cisplatin adducts using this rat monoclonal antibody, Anti-Cisplatin DNA Adducts Antibody, clone ICR4 validated for use in Dot Blot, ELISA & IHC.
ELISA Analysis: A representative lot from an independent laboratory detected Cisplatin DNA Adducts in ELISA (Tilby, M. J., et al. (1991). Cancer Res. 51(1):123-129.; Kothandapani, A., et al. (2011). J Biol Chem. 286(16):14564-14574.; Welters, M. J., et al. (1999). Ann Oncol. 10(1):97-103.; Strobeck, M. W., et al. (2000). Proc Natl Acad Sci USA. 97(14):7748-7753.; Kothandapani, A., et al. (2012). Exp Cell Res. 18(16):1973-1986.).
Immunohistochemistry Analysis: A representative lot from an independent laboratory detected Cisplatin DNA Adducts in Head and Neck Squamous Cell Carcinoma tissues. (Welters, M. J., et al. (1999). Ann Oncol. 10(1):97-103.).
Immunohistochemistry Analysis: A representative lot from an independent laboratory detected Cisplatin DNA Adducts in Head and Neck Squamous Cell Carcinoma tissues. (Welters, M. J., et al. (1999). Ann Oncol. 10(1):97-103.).
Research Category
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Research Sub Category
Chromatin Biology
Chromatin Biology
Jakość
Evaluated by Dot Blot in untreated and Cisplatin treated DNA from HeLa cell lysates.
Dot Blot Analysis: A 1:1,000 dilution of this antibody detected Cisplatin DNA Adducts in 1.0 and 0.5 µg of Cisplatin treated DNA from HeLa cell lysates.
Dot Blot Analysis: A 1:1,000 dilution of this antibody detected Cisplatin DNA Adducts in 1.0 and 0.5 µg of Cisplatin treated DNA from HeLa cell lysates.
Postać fizyczna
Format: Purified
Protein G Purified
Purified rat monoclonal IgG2aκ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Przechowywanie i stabilność
Stable for 1 year at 2-8°C from date of receipt.
Inne uwagi
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Oświadczenie o zrzeczeniu się odpowiedzialności
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Ta strona może zawierać tekst przetłumaczony maszynowo.
Nie możesz znaleźć właściwego produktu?
Wypróbuj nasz Narzędzie selektora produktów.
Kod klasy składowania
12 - Non Combustible Liquids
Klasa zagrożenia wodnego (WGK)
WGK 1
Temperatura zapłonu (°F)
Not applicable
Temperatura zapłonu (°C)
Not applicable
Certyfikaty analizy (CoA)
Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Klienci oglądali również te produkty
M W Strobeck et al.
Proceedings of the National Academy of Sciences of the United States of America, 97(14), 7748-7753 (2000-07-08)
The antiproliferative action of the retinoblastoma tumor suppressor protein, RB, is disrupted in the majority of human cancers. Disruption of RB activity occurs through several disparate mechanisms, including viral oncoprotein binding, deregulated RB phosphorylation, and mutation of the RB gene.
Anbarasi Kothandapani et al.
The Journal of biological chemistry, 286(16), 14564-14574 (2011-03-02)
Using isogenic mouse embryonic fibroblasts and human cancer cell lines, we show that cells defective in base excision repair (BER) display a cisplatin-specific resistant phenotype. This was accompanied by enhanced repair of cisplatin interstrand cross-links (ICLs) and ICL-induced DNA double
Anbarasi Kothandapani et al.
Experimental cell research, 318(16), 1973-1986 (2012-06-23)
Chromatin remodeling complex SWI/SNF plays important roles in many cellular processes including transcription, proliferation, differentiation and DNA repair. In this report, we investigated the role of SWI/SNF catalytic subunits Brg1 and Brm in the cellular response to cisplatin in lung
Yonggen Zou et al.
Oncology letters, 15(1), 1097-1102 (2018-02-06)
As an important chemotherapeutic agent for the treatment of osteosarcoma, the effectiveness of cisplatin is considered to be due to its unique properties, which allow it to penetrate the cell membrane and form various DNA-platinum adducts, resulting in genetic alterations
M J Welters et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 10(1), 97-103 (1999-03-17)
Response to cisplatin-therapy is assumed to be related to the formation of platinum (Pt)-DNA adducts. Measurement of these adducts prior to therapy could be of value to improve cisplatin based cancer therapy. We determined Pt-GG and Pt-AG adduct levels by
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej